Case Series

Anticoagulation failure in pulmonary thromboembolism in COVID-19 pneumonia despite prolonged anticoagulation: A case series

Prakash Sapkota\textsuperscript{a}, Ashish Tamang\textsuperscript{b,\ast}, Sadikshya Bhandari\textsuperscript{a}, Yadavinder Singh\textsuperscript{a}, Rohit Bhasink Shrestha\textsuperscript{b}, Robin Man Karmacharya\textsuperscript{c}, Satish Vaidya\textsuperscript{c}, Swechha Bhatt\textsuperscript{b}

\textsuperscript{a} Department of Internal Medicine, Kathmandu University School of Medical Sciences, Dhalikhel Hospital, Dhalikhel, Kavre, Nepal
\textsuperscript{b} Kathmandu University School of Medical Sciences, Dhalikhel Hospital, Dhalikhel, Kavre, Nepal
\textsuperscript{c} Cardiothoracic and Vascular Surgery Unit, Department of Surgery, Kathmandu University School of Medical Sciences, Dhalikhel Hospital, Dhalikhel, Kavre, Nepal

ARTICLE INFO

Keywords:
Anticoagulant
Case series
COVID-19
Pneumonia
Pulmonary thromboembolism

ABSTRACT

Introduction: Moderate to severely ill patients diagnosed with Coronavirus disease 2019 (COVID-19) pneumonia develop a series of complications and less frequently, we might witness cases of Pulmonary Thromboembolism (PE)-refractory to the standard treatment with Low Molecular Weight Heparin (LMWH). The aim of this case series is to report the presentation and management of pulmonary thromboembolism secondary to COVID-19 pneumonia.

Method: We report a case series of seven cases aged 40–70 who were presented in Dhalikhel Hospital with COVID-19 symptoms in different stages. The case details were extracted from their medical reports of the hospital. The written informed ethical consents were obtained from all the cases and their voluntary participation was assured.

Outcome: The cases in the case series admitted with COVID-19 pneumonia, after diagnostic investigation (Chest x-ray, HRCT, CTPA) were suggestive of COVID-19 Pneumonia with ARDS and pulmonary thromboembolism. The cases received rivaroxaban, a newer anticoagulant-15 mg twice daily for 21 days and after discharge, they were asked to continue once daily doses for 9 weeks. Significant improvement was witnessed, with the presence of additional intervention including rehabilitative chest exercises.

Conclusion: Pulmonary thromboembolism secondary to COVID-19 pneumonia is a life-threatening condition. Rivaroxaban is seen to be very effective in the management of this condition when an anticoagulation failure occurs even after the therapeutic dose of low molecular weight heparin. Future studies may require more scientific investigations to prevent complications even in the early stages of COVID-19.

1. Introduction

Pulmonary thromboembolism (PE) is a hypercoagulative state caused by cytokine storm, hyperactivation of complement factors, and endothelial dysfunction \cite{1}. PE in COVID-19 patients corresponds to nearly 0.5\% of cases presenting to the Emergency Department \cite{1}. However, the incidence is nine times higher when compared to PE in patients with no COVID-19 \cite{1}. This hypercoagulable state has a poor prognosis and can be biochemically detected by increased D-dimer levels \cite{1} (see Tables 1 and 2)

Anticoagulant treatment with low molecular weight heparin (LMWH) should be considered in all hospitalized patients to prevent subsequent organ damage unless contraindicated \cite{2}. It is suggested to improve indices of coagulation dysfunction on administration \cite{3}.

Here, we present seven cases of PE following moderate to severe COVID pneumonia despite the use of prolonged anticoagulation therapy. This article is written in line with PROCESS 2020 criteria \cite{4}.

* Corresponding author.

E-mail addresses: prakash.phulbari@gmail.com (P. Sapkota), ashish.tmg01@gmail.com (A. Tamang), bhandarisadikshya96@gmail.com (S. Bhandari), singhyadvinder1997@gmail.com (Y. Singh), rohitbhasink1@gmail.com (R.B. Shrestha), reachrobin773@gmail.com (R.M. Karmacharya), satish.vaidya.nep@gmail.com (S. Vaidya), swechhabhatt48@gmail.com (S. Bhatt).

https://doi.org/10.1016/j.amsu.2022.104929
Received 30 August 2022; Received in revised form 9 November 2022; Accepted 13 November 2022
Available online 19 November 2022
2049-0801/© 2022 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
2. CASE series

2.1. Case 1

A 42-year-old male presented to Dhulikhel Hospital with a complaint of acute onset fever with chills and rigor for three days. He also had shortness of breath (SOB) at rest for four days which was associated with a one-day history of dry cough, chest pain, and loss of taste. He had no complaints of orthopnea, paroxysmal nocturnal dyspnea (PND), palpitation, or loss of consciousness (LOC). He had no past diagnosis of asthma, chronic obstructive pulmonary disease (COPD), hypertension, or diabetes mellitus.

On examination, his respiratory rate was 30 breaths per minute, and oxygen saturation (SpO2) was 92% with a 2 liter/min oxygen (O2) supply. The reverse transcriptase polymerase chain reaction (RT-PCR) test was positive for COVID-19 infection. As the patient was unstable and could not tolerate computed tomography pulmonary angiography (CTPA), we ordered a high-resolution computed tomography (HRCT) of the chest, which showed patchy ground-glass opacities in bilateral lungs with subpleural blebs (Fig. 1), suggestive of severe COVID-19 pneumonia. We put him on high-flow oxygen through a nasal cannula. Additionally, we added steroids, anticoagulants, and other medications such as paracetamol, fexofenadine, vitamin C and zinc, and rehabilitative chest exercise as a supplemental therapy to improve respiration. We also administered subcutaneous enoxaparin 40 mg twice daily continuously for 14 days, followed by a once-daily dose for 7 days.

After the patient could tolerate low flow O2, we performed CTPA, which revealed a contrast filling defect over the posterior basal segmental branch of the bilateral interlobar artery and anterior segmental branch of bilateral upper lobes (Fig. 2), suggestive of pulmonary thromboembolism. (even after receiving prolonged anticoagulation)

Following this, we started the patient on rivaroxaban, a newer anticoagulant 15 mg twice daily over the first 21 days, followed by a dose of 20 mg once daily for the remaining 9 weeks. We then witnessed a significant improvement; thus, we discharged the patient on the 23rd day of admission with advice to continue rivaroxaban treatment for 9 weeks along with domiciliary oxygen and rehabilitative chest exercises.

The patient is on regular monthly follow-up, and CTPA performed following three months of discharge showed the resolution of the thrombus (Fig. 3).

2.2. Case 2

A 60-year-old hypertensive male presented to our center with complaints of acute onset fever, progressively increasing shortness of breath, and dry cough for a day. He had no orthopnea or PND, fever, headache, anosmia, or LOC. On examination, respiratory rate was 24 breaths per minute, and SpO2 was 95% at 4L/min O2 supplementation.

The chest X-ray and HRCT-chest showed patchy ground-glass opacities in bilateral lungs with subpleural blebs with a computed tomography severity score of 16 out of 25 and CORADS score of 6. We placed him on high-flow oxygen through a nasal cannula and added steroids, anticoagulants, and other supportive medications. We also administered enoxaparin 40 mg subcutaneously twice daily for 14 days due to the high d-dimer value. The dose was gradually tapered. Even so, the patient deteriorated; thus, we shifted him to the COVID ICU and managed him with intermittent continuous positive airway pressure (CPAP). Once the patient was stable even on low flow oxygen, we ordered a CTPA, which showed contrast filling defects over the posterior basal segmental branch of the bilateral interlobar artery, an anterior segmental branch of bilateral upper lobes, and in the mid basal segmental branch of the right interlobar artery (Fig. 4). Therefore, we started the patient on rivaroxaban 15 mg twice daily for the first 21 days, followed by a dose of 20 mg once daily for 9 weeks. more months. We witnessed a significant improvement; hence, we discharged the patient on the 28th day of admission with advice to continue rivaroxaban for 9 weeks along with domiciliary oxygen and rehabilitative chest exercises.

The patient continued regular follow-up, and CTPA performed after three months showed the resolution of the thrombus.

2.3. Case 3

A 53-year-old diabetic male presented to the hospital with complaints of acute onset and progressive shortness of breath at rest for four days, and dry cough for three days, no orthopnea or PND, no history of fever, headache, or loss of consciousness. The respiratory rate was 24 breaths per minute on general examination, and SpO2 was 90% at 15L/min O2 supplementation.

We ordered a chest HRCT, revealing peripheral patchy ground-glass opacity and consolidations in bilateral lungs with secondary pulmonary lobular thickening and subpleural bands suggesting sequelae of COVID-19 pneumonia. The computed tomography severity score was 17 out of 25, and the CORADS score was 6.

For treatment, we administered steroids and anticoagulants along with insulin and other supportive medication, and he was placed on non-invasive ventilation. However, his d-dimer was increasing despite the use of anticoagulants, and thus, we continued him on subcutaneous enoxaparin 40 mg twice daily for 21 days, which was then changed to rivaroxaban. We also ordered CTPA, which showed eccentric contrast filling defect in the upper lobar and segmental branches of the pulmonary artery with a maximum of 50% luminal narrowing and eccentric contrast filling defect noted in the right descending branch of the pulmonary artery with less than 50% of luminal narrowing suggesting pulmonary thromboembolism.

We discharged the patient on the 21st day of admission with anti-diabetic medication. The patient was on a regular follow-up, and CTPA performed after three months showed the resolution of the thrombus.

2.4. Case 4

A 70-year-old male presented to the hospital with acute onset fever for three days, associated with chills. He also had severe shortness of breath.

---

Table 1

| CASE | Sex | Age | Duration of hospital stay | Duration Of LMWH | Duration Of rivaroxaban | Duration Of domiciliary oxygen | Repeated CTPA | Chronic Illness | BMI kg/m² |
|------|-----|-----|--------------------------|------------------|------------------------|-------------------------------|----------------|----------------|-----------|
| 1    | Male| 42  | 23                       | 21               | 3 months               | 3 months                      | Resolved       | Hypertension   | 27.6      |
| 2    | Male| 60  | 28                       | 21               | 3 months               | 3 months                      | Resolved       | Diabetes       | 27.4      |
| 3    | Male| 53  | 21                       | 21               | 3 months               | 2.5 months                    | Resolved       | Hypertension   | 26.2      |
| 4    | Male| 70  | 16                       | 14               | 3 months               | 2 months                      | Resolved       | Parkinsonism   | 22.4      |
| 5    | Male| 40  | 15                       | 14               | 3 months               | 2 weeks                       | Resolved       | Diabetes       | 27.3      |
| 6    | Male| 46  | 30                       | 21               | 3 months               | 3 weeks                       | Resolved       | Hypertension   | 27.9      |
| 7    | Male| 60  | 30                       | 14               | 3 months               | 3 months                      | Resolved       | Hypertension   | 24.9      |
the patient on rivaroxaban 15 mg twice daily for the first 21 days, followed by a dose of 20 mg once daily for 9 weeks. He was discharged on the 16th day with medications. The case was on a regular monthly follow-up for about 3 months, and CTPA performed after three months showed thrombus resolution.

2.5. Case 5

A 42-year-old male presented with complaints of acute onset, progressive and severe SOB for four days which was associated with dry cough and acute onset fever for two days. He had no history of orthopnea, PND, chest pain, or palpitation. He had a history of bronchial asthma, hypertension, and diabetes mellitus and is under medication. His routine blood investigations showed a raised HbA1C of 7.6%, a raised fasting blood sugar of 207 mg/dl, and a raised post-prandial blood sugar of 436 mg/dl. The rest of the reports were within normal limits. We also ordered an HRCT of the chest, which showed peripheral patchy ground-glass opacities in bilateral lungs with segmental and sub-segmental distribution suggestive of COVID pneumonia. His computed tomography score was 11 out of 25, and the CORADS category was 6. We kept him under ICU surveillance and placed him on intermittent CPAP and BiPAP. Anticoagulants, oral steroids, and subcutaneous injection of insulin with other supportive medications were given along with medication for asthma and hypertension. Once the patient was stable in low flow oxygen, we ordered CTPA, which showed a contrast filling defect in the posterior basal segmental branch of the left lower lobe suggestive of pulmonary thromboembolism. Thus, we started him on injection of enoxaparin 60 mg subcutaneously twice daily for the first 21 days, followed by a dose of 20 mg once daily for 9 weeks. He was discharged on the 16th day with medications. The case was on a regular monthly follow-up for about 3 months, and CTPA performed after three months showed the resolution of the thrombus.

2.6. Case 6

A 40-year-old male complained of SOB persisting even at rest for three days along with dry cough for the same duration. He had no orthopnea or PND, no fever, headache, or LOC. His respiratory rate was 28 breaths per minute, and SpO2 was 90% at 15 L/min O2 supplementation. Blood evaluation showed an increase in random blood sugar level of 238 mg/dl with 6.3% of HbA1c.

HRCT was done, which showed multiple areas of ill-defined patchy ground-glass opacities noted in bilateral upper lobes, diffuse ground-glass opacities with air-bronchograms, and smooth interlobular septal thickening noted in bilateral lungs, predominantly in the perihilar location with cardiomegaly which was likely due to cardiogenic pulmonary edema. Echocardiography was done, which showed no regional wall motion abnormality.

Thus, we diagnosed the patient with severe COVID pneumonia and started him on injection of enoxaparin 60 mg subcutaneously twice daily for 14 days due to higher levels of d-dimer. We also gave him steroids with other supportive medications. He was placed on non-invasive ventilation with intermittent CPAP and BiPAP. Once the case was stable on low flow oxygen, we ordered CTPA and showed the contrast filling defect in the subsegmental branch of the posterior basal segment of bilateral pulmonary arteries, and multiple areas of ill-defined patchy ground-glass opacities noted in bilateral upper lobes, and diffuse ground-glass opacities with air-bronchograms and smooth interlobular septal thickening and subpleural bands in bilateral lungs. It was a

Table 2

| Parameters                        | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 | Reference Range |
|----------------------------------|--------|--------|--------|--------|--------|--------|--------|-----------------|
| Complete Blood Count ( x 10^3/μL)| 4.7    | 6.5    | 7.9    | 8.5    | 10.9   | 10.9   | 47     | 4.0-11.0        |
| Neutrophil Count %               | 78     | 85     | 92     | 88     | 93     | 86     | 78     | 45-75           |
| Lymphocyte Count %               | 15     | 11     | 4      | 8      | 4      | 8      | 15     | 20-45           |
| Hemoglobin (gm/dl)               | 14.3   | 12.5   | 13.2   | 13.3   | 15.1   | 13     | 14.3   | 12-16           |
| Platelets count ( x 10^3/μL)     | 271    | 317    | 162    | 135    | 196    | 148    | 150    | 150-450         |
| CRP Quantitative mg/L            | 152    | 150    | 145    | 136    | 32     | 159    | 150    | <5.0            |
| D-Dimer at the time of admission ng/ml | 3.8  | 1975   | 4      | N/A    | 9.5    | 3.7    | 1975   | <500            |
| ABG P02 mm of Hg                 | 54     | 58     | 48     | 40     | 58     | 62     | 53     | 80-100          |
Fig. 2. CTPA shows a contrast filling defect over the posterior basal segmental branch of the bilateral interlobar artery and anterior segmental branch of bilateral upper lobes as evidence of PE.

Fig. 3. Follow-up CTPA showing resolution of previous contrast filling defect after rivaroxaban therapy.

Fig. 4. CTPA showing contrast filling defects over the posterior basal segmental branch of the bilateral interlobar artery, an anterior segmental branch of bilateral upper lobes, and in the mid basal segmental branch of the right interlobar artery.
2.7. Case 7

A 60-year-old male with hypertension presented with acute onset fever for three associated with chills and rigors. He also had a sudden onset of progressively increasing SOB for the same duration, which was present even at rest, and was associated with dry cough and chest pain. He had no orthopnea or PND, no fever, headache, or LOC.

We discharged the patient on the 30th day of admission with the advice of medication as in prior cases. The patient is on a regular monthly follow-up, and CTPA performed after three months showed the resolution of the thrombus.

Fig. 5. CTPA showing a contrast filling defect in the posterior basal segmental branch, a few subsegmental branches of bilateral interlobar pulmonary arteries, and the right upper lobe segmental branch.

3. Discussion

PE is a fatal condition usually associated with right ventricular dysfunction [5]. Many studies have suggested a correlation between COVID and increased thrombosis risk [1]. The incidence of pulmonary thrombosis in COVID-19-infected patients has been reported to be as high as 79% [6]. As PE and COVID-19 pneumonia share common signs and symptoms, differentiating PE in patients with COVID-19 is challenging [7]. Despite the use of therapeutic dose anticoagulation, 23% of the admitted COVID-19 patients disclosed pulmonary embolism [8]. PE engages multifactorial unified pathogenesis, which includes increased risk of thrombosis secondary to increased cytokines, endothelial injury, platelet activation, neutrophil traps, complement activity, hypoxia, and invasion of COVID-19 into the endothelial cells via angiotensin-converting enzyme 2 (ACE2) receptors as well as the presence of antiphospholipid antibodies [8].

PE is nine times more common in COVID-19 [1]. Apart from the common cause of thrombosis i.e. immobility and severe illness; studies have analyzed established cardiovascular risk factors in the development of VTE (Venous thromboembolism) in COVID-19 and concluded that adiposity, older age (68–75 years) and smoking were consistently associated with a higher risk of VTE where adiposity showed a stronger association in non-COVID-19 cases [2]. Other major unprovoked risk factors listed were hypertension, metabolic syndrome, air pollution, long-haul travel, and thrombophilias [10]. In the COVID-19 cases, the information on the associated factors in stratification of the risk factors in the patients to initiate the required prophylaxis. This case series presented older adult cases with at least one comorbidity and hypertension was the most common one. The series could not present other risk factors in detail.

Most of the signs and symptoms of PE and COVID-19 pneumonia are similar, therefore diagnosing PE in COVID-19 patients can be difficult and often lead to misdiagnosis, mistreatment, or a delay in treatment initiation, under-diagnosis of the condition may raise the risk of morbidity and mortality. These cases in this case series had confusing signs and symptoms similar to the findings of other studies.

In patients with positive COVID-19 infection, CT progression and increasing D-dimer levels are regarded as the most critical criteria suggesting underlying PE which is typically detected during the second week of infection and necessitates the use of CTPA to exclude or confirm PE [11]. The confirmation can provide an indication for the use of anticoagulation in either prophylactic or therapeutic doses [11]. The cases in the series underwent investigations similar to other studies such as CT, D-dimer, CTPA, and others, reflecting the need for the appropriate, timely, and precise diagnosis.

Several guidelines for both prophylaxis and treatment of thrombosis in hospitalized COVID-19 cases have been published. International Society of Thrombosis and Haemostasis (ISTH) interim guidelines recommend prophylactic dose low molecular weight heparin (LMWH) be considered in all patients, including non-critically ill, who require hospital admission for COVID-19 infection [2]. However, the CHEST guideline update published in the February of 2022 has made recommendations for acutely ill hospitalized patients with COVID-19 who have a low risk of bleeding to use therapeutic dose heparin (UFH or LMWH) over the current standard dose anticoagulant thromboprophylaxis [12]. However, in patients who are acutely ill but not receiving therapeutic doses of heparin, the current standard dose of anticoagulant...
thromboprophylaxis over intermediate-dose anticoagulation is recommended [12]. Moreover, in critically ill patients with COVID-19, current standard dose anticoagulant thromboprophylaxis (with UFH or LMWH) over both therapeutic dose anticoagulation and intermediate-dose anticoagulation is recommended [12]. As recommended by the guidelines, all the indexed cases in this case series received LMWH in therapeutic doses from the first day of hospital admission. After the stability under low flow oxygen, CTPA was done resulting in the diagnosis of PE in all the cases.

A study highlighted that among the cases of severe pneumonia and high BMI, the outcome of the prophylactic anticoagulation was poorer than the therapeutic anticoagulation, suggesting less effective thromboprophylaxis among cases with elevated BMI [14]. The cases in this case series reported failure in thromboprophylaxis and raised BMI levels (i.e. 24.9 kg/m²).

Some studies did not support the use of higher than standard doses for prophylactic anticoagulation in critically ill patients with COVID-19 due to the lack of immediately visible benefit and the risk of bleeding events. An experimental study conducted among 600 critically ill cases reported that the intermediate-dose anticoagulation with LMWH daily was not superior to standard prophylactic anticoagulation with LMWH daily in reducing the composite outcome of venous or arterial thrombosis [13]. The study also revealed that the bleeding events were rare but major and clinically relevant bleeding events were more frequent with intermediate-dose anticoagulation, albeit not significantly [13]. The indexed cases in this case series as well as other admitted cases during the COVID-19 pandemic also had no clinically relevant bleeding events or signs of pulmonary thrombosis even after therapeutic anticoagulation reflecting failure in thromboprophylaxis.

The cases in this case series received Vitamin C, following the evidence of increased recovery rate shown by reanalysis of the COVID A to Z Trial [14]. The chest exercises might improve respiratory functions enhancing the quality of life of the cases after their hospital stay, however, this has less evidence of enhancement in the COVID-19 treatment [17]. The cases presented in the case series adapted the chest exercise as the supplementary therapy, which added support to the cases in recovery and rehabilitation.

A study found that the group treated with glucocorticoids had an increased level of D-dimer than the control group. The heightened level of D-dimer elevates the risk of venous thromboembolism in COVID-19 patients by several folds [11]. This case series also presented cases with raised D-dimer levels and the occurrence of PE, despite using anticoagulants.

A multicenter clinical trial concluded that rivaroxaban monotherapy contributed to reducing the length of hospital stay, and decreasing the cost of treatment while being efficacious and well-tolerated in patients with PE [15]. In this case series, the cases were confirmed PE using CTPA, and then they were treated with the novel anticoagulant rivaroxaban.

Several current randomized controlled trials (RCTs) are testing antithrombotic treatments in COVID-19 patients which includes antiplatelet agents, anticoagulants, fibrinolytic agents, or combinations of these agents. At ClinicalTrials.gov, 76 studies of antithrombotic drugs for COVID-19 patients have been registered [16]. In clinical trials databases, 25 intervention trials are registered with 15 related to the use of LMWH among which six studies have been completed and the rest are ongoing [17]. 11 RCTs of antithrombotic treatment in outpatients with COVID-19 have been reported, with enoxaparin, DOACs, aspirin, and sulodexide being studied [18].

The study of the COVID-19 cases in this case series is the first kind in Dhulikhel Hospital and thus will be evidence for future researchers and physicians. This case series would have been more comprehensive and diverse, integrating cases from other institutions. This would have provided more generalized findings. Further detailing of the cases would have provided more information to the readers. Future researchers may explore improving the study design considering the limitation of the design, for precise generalization.

4. Conclusion

VTE following COVID-19 infection has led to the formation of many guidelines that recommend the use of a therapeutic dose of anticoagulants in hospitalized patients with COVID-19 without contraindications. Based on this, we used therapeutic doses of LMWH followed by rivaroxaban which showed good efficacy with complete resolution of the thrombus during the three months follow-ups and no bleeding episodes. With the COVID-19 pandemic still evolving, further research on individualized drug use is advisable for further risk stratification and preventing complications.

Ethical approval

We have obtained written informed consent from the patients for the publication of this case series.

Sources of funding

None.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Registration of research studies

N/A.

Patient perspective

After explaining to the patient about the entire project and its benefit for clinicians and patients globally, the patients were extremely happy.

Author contribution

PS: Patient care, concept, manuscript writing, editing, review, guarantor; AT: Concept, Manuscript writing, editing and review; RBS: Manuscript writing and editing; SB: Manuscript writing and editing; YS: Manuscript writing and editing; RMK: Management of the case; SV: Management of the case; SB: Concept, Manuscript writing, editing and review.

Guarantor

Dr Prakash Sapkota.

Provenance and peer review

Not commissioned, externally peer reviewed.

Declaration of competing interest

None.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.amsu.2022.104929.
References

[1] Miró Ò, S. Jiménez, A. Mehazaa, et al., Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome, Eur. Heart J. 42 (2021) 3127–3142.

[2] J. Thachil, N. Tang, S. Gando, et al., ISTH interim guidance on recognition and management of coagulopathy in COVID-19, J. Thromb. Haemostasis 18 (2020), https://doi.org/10.1111/jth.14610, Epub ahead of print May.

[3] C. Shi, C. Wang, H. Wang, et al., The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective cohort study, Clin. Transl. Sci. 13 (2020) 1087–1095.

[4] R.A. Agha, C. Sohrabi, G. Mathew, et al., The PROCESS 2020 guideline: updating consensus preferred reporting of CasE series in surgery (PROCESS) guidelines, Int. J. Surg. 84 (2020) 231–235.

[5] M.V. Huisman, S. Barco, S.C. Cannegieter, et al., Pulmonary embolism, Nat. Rev. Dis. Prim. 4 (2018), 18028.

[6] J. Nahum, T. Morichau-Beauchant, F. Daviaud, et al., Venous thrombosis among critically ill patients with Coronavirus disease 2019 (COVID-19), JAMA Netw. Open 3 (2020), e2010478.

[7] H.D. Poor, Pulmonary thrombosis and thromboembolism in COVID-19, Chest 160 (2021) 1471–1480.

[8] V. Carfora, G. Spiniello, R. Ricciolino, et al., Anticoagulant treatment in COVID-19: a narrative review, J. Thromb. Thrombolysis 51 (2021) 642–648.

[9] D. Dubinski, F. Keil, S.-Y. Won, et al., Pulmonary embolism in neurocritical care—introduction of a novel grading system for risk stratification: the Frankfurt AMBOS score, Neuron. Surg. Rev. 44 (2021) 1165–1171.

[10] S.Z. Goldhaber, H. Bounameaux, Pulmonary embolism and deep vein thrombosis, Lancet 379 (2012) 1835–1846.

[11] A. Yassin, M.A. Abdelkader, R.M. Mohammed, et al., CT pulmonary angiography in COVID-19 pneumonia: relationship between pulmonary embolism and disease severity, Egyptian J. Radiol. Nucl. Med. 52 (2021) 1–8.

[12] L.K. Moores, T. Tritschler, S. Brosnanah, et al., Thromboprophylaxis in patients with COVID-19: a brief update to the chest guideline and expert panel report, Chest (2022), https://doi.org/10.1016/j.chest.2022.02.006, Epub ahead of print 12 February.

[13] Inspiration Investigators, P. Sadeghipour, A.H. Talasaz, et al., Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial, JAMA 325 (2021) 1620–1630.

[14] A. Carr, E. Chalker, Vitamin C may increase the recovery rate of outpatient cases of SARS-CoV-2 infection by 70%: reanalysis of the COVID A to Z randomized clinical trial, Front. Immunol. 12 (2021), 674681.

[15] B. Van Bellen, L. Bamber, F. Correa de Carvalho, et al., Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism, Carr. Med. Res. Opin. 30 (2014) 829–837.

[16] Available from: Covid 19 anticoagulation [internet]. ClinicalTrials.gov https://clinicaltrials.gov/ct2/results?term=Covid%2019%20anticoagulation&Search=Sea rch&fbclid=IwAR2GiNlx-gFtu6oadjlST2X-USS_ihD0OxQVqfLMy8TgfD346g.tJa OoQc. (Accessed 25 August 2022).

[17] Covid-19 SARS-COV2 [internet], Available from: https://www.clinicaltrials.gov/ct2/results?cond=covid&term=covid-19+SARS-COV2&type=Intr&result=&cris=&ekage=s&gdr&kintr=LMWH&title=&o utc=&aspons=&lead=&cty=&state=&city=&dist=&loct=&rscnub=&strd s=&strd_e=&prcd_s=&prcd_e=&&sfpd_s=&sfpd_e=&&rnpd_s=&&rnpd_e=&&l upd_s=&&lupd_e=&

[18] A.H. Talasaz, P. Sadeghipour, H. Kakavand, et al., Recent randomized trials of antithrombotic therapy for patients with COVID-19: JACC state-of-the-art review, J. Am. Coll. Cardiol. 77 (2021) 1903–1921.